Nexavar
Nexavar ingredients
| Active ingredient | Strength |
|---|---|
| Sorafenib | 200 mg/1 |
What Nexavar is used for
The FDA lists the approved uses on the official label (below). In the EU, sorafenib is approved as Nexavar for:
Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Nexavar
- Generic name
- Sorafenib
- Made by
- Bayer HealthCare Pharmaceuticals Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA021923
- On the US market since
- 2005
Official information
- Nexavar prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Sorafenib)
In India
- Sorafenib: 8 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nexavar?
Nexavar (Sorafenib) is a cancer medicine made by Bayer HealthCare Pharmaceuticals Inc., approved by the US FDA.
What are the ingredients of Nexavar?
Nexavar contains Sorafenib (200 mg/1).
Is Nexavar approved in Europe?
The same active substance is approved in the EU as Nexavar.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA